No Data
No Data
Changes in Hong Kong stocks | Federal Pharmaceuticals (03933) rose more than 3%, and the winning bidder in Group A across the insulin collection line is optimistic about its accelerated release
Federal Pharmaceuticals (03933) rose more than 3%. As of press release, it rose 3.41% to HK$9.71, with a turnover of HK$22.403,900.
Federal Pharmaceuticals (03933.HK): Amoxicillin Clavulanate Potassium Tablets passed the consistent evaluation of generic drug quality and efficacy
On April 24, Gelonghui Pharmaceuticals (03933.HK) announced that amoxicillin clavulanate potassium tablets (specification: 0.375g) declared by the Zhongshan Branch of Zhuhai Federal Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, were approved by the China National Drug Administration and passed the consistent evaluation of the quality and efficacy of generic drugs. Amoxicillin clavulanate potassium tablets are a penicillin-type broad-spectrum antibiotic. Clinically, it is commonly used to treat infections caused by beta-lactamase-producing bacteria, such as respiratory infections, skin and soft tissue infections, and urinary infections. Its curative effect is clear, safe and reliable, and is clinically based
Guojin Securities: Continued increase in domestic insulin share is expected to drive continued growth in performance
Since May 2022, national special insulin collection has been launched in various provinces and cities. While the price of insulin products has declined, the domestic substitution process has greatly accelerated.
CICC: Maintaining Federal Pharmaceuticals (03933.HK)'s “outperforming the industry” rating target price of HK$10.5
CICC released a research report stating that it maintains the “outperforming industry” rating of Federal Pharmaceuticals (03933.HK), the profit forecast remains unchanged, and the target price is HK$10.5. On April 23, the Joint Pharmaceutical Procurement Office of the State Organization issued the “Announcement of the Results of the National Centralized Drug Procurement (Special Insulin Special) Selection Results”, and all 6 products declared by Federal Pharmaceuticals won the bid in Group A.
Federal Pharmaceuticals (03933.HK): Group A won the bid for the entire insulin collection line, hoping for an opportunity to increase share
Company News On April 23, the Joint Pharmaceutical Procurement Office of the State Organization issued the “National Centralized Drug Procurement (Insulin Special Continuation) Proposed Selection Results Announcement”. All 6 products declared by Federal Pharmaceuticals won the bid 1 in Group A. Review insulin sets
Federal Pharmaceuticals (03933.HK): The company's insulin products are to be selected for centralized drug procurement in the country
Gelonghui, April 23 | Federal Pharmaceutical (03933.HK) announced that the company's wholly-owned subsidiaries, Zhuhai Federal Pharmaceutical Co., Ltd. and the Zhongshan Branch of Zhuhai Federal Pharmaceutical Co., Ltd. participated in the bidding process for centralized national drug procurement (insulin special continuation) (“insulin special continuation”) organized by the State Organization Drug Joint Procurement Office on April 23, 2024. The company's insulin products are to be selected for this centralized procurement. All of the company's insulin products participated in this insulin collection competition, and all products were selected in Class A. In 2023, the company will sell the total sales of the products to be selected above
No Data